Status: Not yet recruiting
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
This study will examine the effects of Tirzepatide (TZP), a glucagon-like peptide 1 (GLP1) - gastric inhibitory peptide (GIP) co-agonist, on metabolism in type 1 diabetes (T1D). Research participants with T1D will undergo measures of insulin sensitivity, and hormone levels post-meal, post-hypoglycemia and during the overnight period. These measures will be performed prior to, and after 6 weeks of treatment with TZP or placebo.
Participants needed: 44
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Victor Chang Cardiac Research InstituteUpdated: May 19, 2026Locations: 1
Eligibility criteria
age 18-65 years [+4]
TZP or GLP-1 receptor agonist in last 3 months; metformin or sodium glucose co-t... [+9]